Novacyt , the cellular diagnostics company offering products and services for cancers and infectious diseases, announced that its molecular testing division, Primerdesign Ltd. has signed an exclusive supply agreement worth at least $3 million with Genesis Diagnostics, a US-based diagnostic laboratory.
The partnership will consist of Primerdesign developing and supplying 384 well plate molecular assay panels for respiratory, women’s health, sexually transmitted, wound and urinary tract infections for Genesis Diagnostics to use in its clinical service laboratory.
Primerdesign will also be appointed as the exclusive product manufacturer of the panel for a minimum of five years. Product supply is expected to begin in early 2019 and General Diagnostics will purchase at least $600,000 worth of the product a year.
CEO of Novacyt, Graham Mullis believes the agreement will expand Novacyt’s “geographic reach” and “the minimum revenues expected from this partnership will further support our investment in our B2B partnerships strategy.”
For more news and updates on Novacyt:
